Your browser doesn't support javascript.
loading
Structure of the cell-binding component of the Clostridium difficile binary toxin reveals a di-heptamer macromolecular assembly.
Xu, Xingjian; Godoy-Ruiz, Raquel; Adipietro, Kaylin A; Peralta, Christopher; Ben-Hail, Danya; Varney, Kristen M; Cook, Mary E; Roth, Braden M; Wilder, Paul T; Cleveland, Thomas; Grishaev, Alexander; Neu, Heather M; Michel, Sarah L J; Yu, Wenbo; Beckett, Dorothy; Rustandi, Richard R; Lancaster, Catherine; Loughney, John W; Kristopeit, Adam; Christanti, Sianny; Olson, Jessica W; MacKerell, Alexander D; Georges, Amedee des; Pozharski, Edwin; Weber, David J.
Affiliation
  • Xu X; City University of New York Advanced Science Research Center, City University of New York, New York, NY 10017.
  • Godoy-Ruiz R; PhD Program in Biochemistry, The Graduate Center, City University of New York, New York, NY 10017.
  • Adipietro KA; Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Peralta C; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850.
  • Ben-Hail D; The Center for Biomolecular Therapeutics, The University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Varney KM; Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Cook ME; The Center for Biomolecular Therapeutics, The University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Roth BM; City University of New York Advanced Science Research Center, City University of New York, New York, NY 10017.
  • Wilder PT; City University of New York Advanced Science Research Center, City University of New York, New York, NY 10017.
  • Cleveland T; Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Grishaev A; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850.
  • Neu HM; The Center for Biomolecular Therapeutics, The University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Michel SLJ; Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Yu W; The Center for Biomolecular Therapeutics, The University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Beckett D; Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Rustandi RR; Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Lancaster C; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850.
  • Loughney JW; The Center for Biomolecular Therapeutics, The University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Kristopeit A; National Institute of Standards, Rockville, MD 20899.
  • Christanti S; National Institute of Standards, Rockville, MD 20899.
  • Olson JW; University of Maryland School of Pharmacy, University of Maryland, Baltimore, MD 21201.
  • MacKerell AD; University of Maryland School of Pharmacy, University of Maryland, Baltimore, MD 21201.
  • Georges AD; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850.
  • Pozharski E; The Center for Biomolecular Therapeutics, The University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201.
  • Weber DJ; University of Maryland School of Pharmacy, University of Maryland, Baltimore, MD 21201.
Proc Natl Acad Sci U S A ; 117(2): 1049-1058, 2020 01 14.
Article in En | MEDLINE | ID: mdl-31896582
Targeting Clostridium difficile infection is challenging because treatment options are limited, and high recurrence rates are common. One reason for this is that hypervirulent C. difficile strains often have a binary toxin termed the C. difficile toxin, in addition to the enterotoxins TsdA and TsdB. The C. difficile toxin has an enzymatic component, termed CDTa, and a pore-forming or delivery subunit termed CDTb. CDTb was characterized here using a combination of single-particle cryoelectron microscopy, X-ray crystallography, NMR, and other biophysical methods. In the absence of CDTa, 2 di-heptamer structures for activated CDTb (1.0 MDa) were solved at atomic resolution, including a symmetric (SymCDTb; 3.14 Å) and an asymmetric form (AsymCDTb; 2.84 Å). Roles played by 2 receptor-binding domains of activated CDTb were of particular interest since the receptor-binding domain 1 lacks sequence homology to any other known toxin, and the receptor-binding domain 2 is completely absent in other well-studied heptameric toxins (i.e., anthrax). For AsymCDTb, a Ca2+ binding site was discovered in the first receptor-binding domain that is important for its stability, and the second receptor-binding domain was found to be critical for host cell toxicity and the di-heptamer fold for both forms of activated CDTb. Together, these studies represent a starting point for developing structure-based drug-design strategies to target the most severe strains of C. difficile.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Bacterial Proteins / Bacterial Toxins / Clostridioides difficile / ADP Ribose Transferases / Enterotoxins Limits: Animals Language: En Year: 2020 Type: Article

Full text: 1 Database: MEDLINE Main subject: Bacterial Proteins / Bacterial Toxins / Clostridioides difficile / ADP Ribose Transferases / Enterotoxins Limits: Animals Language: En Year: 2020 Type: Article